据报道，基于炎症的预后参数是各种肿瘤疾病的有用工具。胰腺导管腺癌（PDAC）的特点是死亡率高，因此非常需要可靠的预后标志物。然而，文献中关于不同可用评分的疗效仍存在不一致。这项回顾性单项研究纳入了 2000 年 1 月至 2018 年 12 月在埃尔兰根大学医院接受 PDAC 初次切除术的 207 例患者。中心研究。不同的生物标志物，包括术前中性粒细胞-淋巴细胞比值（NLR）、血小板-淋巴细胞比值（PLR）、C反应蛋白（CRP）-白蛋白比值（CAR）、淋巴细胞-CRP比值（LCR）、预后营养分析了 PNI 指数 (PNI) 和改良格拉斯哥预后评分 (mGPS) 预测总生存期 (OS) 的能力。在我们的队列中，中位总生存期为 20.7 个月。在研究的生物标志物中，NLR 和 PNI 被确定为独立的预后标志物（风险比 (HR) 1.6 (1.0-2.5)，p = 0.048 和 HR 0.6 (0.4-0.9)，p = 0.018），而 PLR、CAR、LCR mGPS 在多变量分析中没有达到显着性。亚组分析显示，NLR 和 PNI 的预后价值在局部晚期肿瘤分期（pT3/4 和 pN ）中尤为明显。NLR 和 PNI 可以作为评估接受胰腺切除术的 PDAC 患者预后的有价值的工具，尤其是在局部晚期肿瘤阶段。然而，当前文献中相互矛盾的结果强调需要进一步的前瞻性研究来验证这些发现。

Prognostic inflammation-based parameters have been reported as useful tools in various oncologic diseases. Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high mortality rate, making reliable prognostic markers highly desirable. However, there is still inconsistency in the literature regarding the efficacy of the different available scores.A total of 207 patients, who underwent primary resection of PDAC from January 2000 to December 2018 at the University Hospital of Erlangen, were included in this retrospective single-center study. Different biomarkers, including the preoperative neutrophil-lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), the c-reactive protein (CRP)-albumin ratio (CAR), the lymphocyte-CRP ratio (LCR), the prognostic nutritional index (PNI) and the modified Glasgow prognostic score (mGPS) were analyzed for their ability to predict overall survival (OS).In our cohort, the median overall survival was 20.7 months. Among the investigated biomarkers, NLR and PNI were identified as independent prognostic markers (Hazard Ratio (HR) 1.6 (1.0-2.5), p = 0.048 and HR 0.6 (0.4-0.9), p = 0.018), whereas PLR, CAR, LCR and mGPS did not reach significance in the multivariate analysis. Subgroup analysis revealed that the prognostic value of NLR and PNI is particularly evident in locally advanced tumor stages (pT3/4 and pN+).The NLR and PNI could serve as valuable tools for estimating prognosis in patients with PDAC undergoing pancreatic resection in curative intention, especially in locally advanced tumor stages. However, conflicting results in the current literature highlight the need for further prospective studies to validate these findings.